Free Trial

Klotho Neurosciences Q2 2024 Earnings Report

Klotho Neurosciences logo
$0.44 -0.01 (-1.56%)
As of 04:00 PM Eastern

Klotho Neurosciences EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Klotho Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Klotho Neurosciences Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Klotho Neurosciences Earnings Headlines

Donald Trump is about to free crypto from its chains …
With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.
See More Klotho Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Klotho Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Klotho Neurosciences and other key companies, straight to your email.

About Klotho Neurosciences

Klotho Neurosciences (NASDAQ:KLTO), a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

View Klotho Neurosciences Profile

More Earnings Resources from MarketBeat